No differences in CSS were observed in patients with stage I–II CRC irrespective of mutated or wild-type status of KRAS/NRAS/BRAF/PIK3CA, although significant differences in CSS was observed for stage III and IV patients with mutated and wild-type tumors. Here, NRAS is linked to colorectal carcinoma.